Last edition
News about "Celltrion"
Prometheus Laboratories Collaborates with Celltrion for Anser Testing
Prometheus is the first specialty lab to validate TDM testing for both intravenous and subcutaneous infliximab, supporting the growing demand for at-home treatment options.
Celltrion | 28/08/2025 | By Dineshwori
Celltrion Secures US FDA Approval for Expanded Indication for AVTOZMA
Celltrion has received FDA approval for an expanded indication of AVTOZMA IV (tocilizumab-anoh) to treat cytokine release syndrome (CRS), achieving full indication parity with reference biologic ACTEMRA IV in the US.
Celltrion | 07/08/2025 | By Mrinmoy Dey
Celltrion to Acquire US Biologics Plant to Counter Potential Pharma Tariffs
Celltrion has been selected as the preferred bidder to acquire a large biologics manufacturing plant in the United States —a strategic move aimed at insulating the company from potential US pharmaceutical tariffs.
Celltrion | 30/07/2025 | By Dineshwori | 258
Celltrion Announces Three-Stage Strategy to Counter Trump's Pharma Tariff Plan
Celltrion has announced its response strategy to US President Donald Trump’s plan to impose tariffs on pharmaceuticals.
Celltrion | 10/07/2025 | By Dineshwori | 305
Celltrion's YUFLYMA Achieves FDA Interchangeable Status
YUFLYMA is an FDA-approved, high-concentration (100mg/mL) and citrate-free formulation of Humira® biosimilar, approved for multiple inflammatory indications.
Celltrion | 15/04/2025 | By Abha | 192
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy